Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion

J P Thyssen; M S de Bruin-Weller; A S Paller; Y A Leshem; C Vestergaard; M Deleuran; A M Drucker; R Foelster-Holst; C T Hoffmann; K Eyerich; A Taieb; J C Su; T Bieber; M J Cork; L F Eichenfield; E Guttman-Yassky; A Wollenberg

doi:10.1111/jdv.15608

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion

J P Thyssen, M S de Bruin-Weller, A S Paller, Y A Leshem, C Vestergaard, M Deleuran, A M Drucker, R Foelster-Holst, C T Hoffmann, K Eyerich, A Taieb, J C Su, T Bieber, M J Cork, L F Eichenfield, E Guttman-Yassky, A Wollenberg

Research output: Contribution to journal › Journal article › Research › peer-review

49 Citations (Scopus)

44 Downloads (Pure)

Abstract

BACKGROUND: Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with dupilumab.

OBJECTIVE: To survey opinions and experience about conjunctivitis occurring in AD, including those during dupilumab treatment in a group of AD experts from the International Eczema Council (IEC).

METHODS: Electronic survey and in-person discussion of management strategies.

RESULTS: Forty-six (53.5%) IEC members from 19 countries responded to the survey. Consensus was reached for several statements regarding diagnostic workup, referral and treatment. IEC members suggest that patients with AD should (i) routinely be asked about ocular complaints or symptoms, (ii) obtain information about the potential for conjunctivitis before starting dupilumab therapy and (iii) if indicated, be treated with dupilumab despite previous or current conjunctivitis. In cases of new-onset conjunctivitis, there was consensus that dupilumab treatment should be continued when possible, with appropriate referral to an ophthalmologist.

LIMITATIONS: The study relies on expert opinion from dermatologists. Responses from few dermatologists without dupilumab access were not excluded from the survey.

CONCLUSION: The IEC recommends that dermatologists address conjunctivitis in patients with AD, especially during treatment with dupilumab.

Original language	English
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	33
Issue number	7
Pages (from-to)	1224-1231
Number of pages	8
ISSN	0926-9959
DOIs	https://doi.org/10.1111/jdv.15608
Publication status	Published - Jul 2019

Access to Document

10.1111/jdv.15608Licence: CC BY-NC 4.0

Thyssen_et_al-2019-Journal_of_the_European_Academy_of_Dermatology_and_VenereologyFinal published version, 167 KBLicence: CC BY-NC 4.0

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Thyssen, J. P., de Bruin-Weller, M. S., Paller, A. S., Leshem, Y. A., Vestergaard, C., Deleuran, M., Drucker, A. M., Foelster-Holst, R., Hoffmann, C. T., Eyerich, K., Taieb, A., Su, J. C., Bieber, T., Cork, M. J., Eichenfield, L. F., Guttman-Yassky, E., & Wollenberg, A. (2019). Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion. Journal of the European Academy of Dermatology and Venereology, 33(7), 1224-1231. https://doi.org/10.1111/jdv.15608

@article{68861dac9a464799b7e19a5611d1b316,

title = "Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion",

abstract = "BACKGROUND: Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with dupilumab.OBJECTIVE: To survey opinions and experience about conjunctivitis occurring in AD, including those during dupilumab treatment in a group of AD experts from the International Eczema Council (IEC).METHODS: Electronic survey and in-person discussion of management strategies.RESULTS: Forty-six (53.5%) IEC members from 19 countries responded to the survey. Consensus was reached for several statements regarding diagnostic workup, referral and treatment. IEC members suggest that patients with AD should (i) routinely be asked about ocular complaints or symptoms, (ii) obtain information about the potential for conjunctivitis before starting dupilumab therapy and (iii) if indicated, be treated with dupilumab despite previous or current conjunctivitis. In cases of new-onset conjunctivitis, there was consensus that dupilumab treatment should be continued when possible, with appropriate referral to an ophthalmologist.LIMITATIONS: The study relies on expert opinion from dermatologists. Responses from few dermatologists without dupilumab access were not excluded from the survey.CONCLUSION: The IEC recommends that dermatologists address conjunctivitis in patients with AD, especially during treatment with dupilumab.",

author = "Thyssen, {J P} and {de Bruin-Weller}, {M S} and Paller, {A S} and Leshem, {Y A} and C Vestergaard and M Deleuran and Drucker, {A M} and R Foelster-Holst and Hoffmann, {C T} and K Eyerich and A Taieb and Su, {J C} and T Bieber and Cork, {M J} and Eichenfield, {L F} and E Guttman-Yassky and A Wollenberg",

year = "2019",

month = jul,

doi = "10.1111/jdv.15608",

language = "English",

volume = "33",

pages = "1224--1231",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Elsevier",

number = "7",

}

Thyssen, JP, de Bruin-Weller, MS, Paller, AS, Leshem, YA, Vestergaard, C, Deleuran, M, Drucker, AM, Foelster-Holst, R, Hoffmann, CT, Eyerich, K, Taieb, A, Su, JC, Bieber, T, Cork, MJ, Eichenfield, LF, Guttman-Yassky, E & Wollenberg, A 2019, 'Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion', Journal of the European Academy of Dermatology and Venereology, vol. 33, no. 7, pp. 1224-1231. https://doi.org/10.1111/jdv.15608

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion. / Thyssen, J P; de Bruin-Weller, M S; Paller, A S et al.
In: Journal of the European Academy of Dermatology and Venereology, Vol. 33, No. 7, 07.2019, p. 1224-1231.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion

AU - Thyssen, J P

AU - de Bruin-Weller, M S

AU - Paller, A S

AU - Leshem, Y A

AU - Vestergaard, C

AU - Deleuran, M

AU - Drucker, A M

AU - Foelster-Holst, R

AU - Hoffmann, C T

AU - Eyerich, K

AU - Taieb, A

AU - Su, J C

AU - Bieber, T

AU - Cork, M J

AU - Eichenfield, L F

AU - Guttman-Yassky, E

AU - Wollenberg, A

PY - 2019/7

Y1 - 2019/7

N2 - BACKGROUND: Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with dupilumab.OBJECTIVE: To survey opinions and experience about conjunctivitis occurring in AD, including those during dupilumab treatment in a group of AD experts from the International Eczema Council (IEC).METHODS: Electronic survey and in-person discussion of management strategies.RESULTS: Forty-six (53.5%) IEC members from 19 countries responded to the survey. Consensus was reached for several statements regarding diagnostic workup, referral and treatment. IEC members suggest that patients with AD should (i) routinely be asked about ocular complaints or symptoms, (ii) obtain information about the potential for conjunctivitis before starting dupilumab therapy and (iii) if indicated, be treated with dupilumab despite previous or current conjunctivitis. In cases of new-onset conjunctivitis, there was consensus that dupilumab treatment should be continued when possible, with appropriate referral to an ophthalmologist.LIMITATIONS: The study relies on expert opinion from dermatologists. Responses from few dermatologists without dupilumab access were not excluded from the survey.CONCLUSION: The IEC recommends that dermatologists address conjunctivitis in patients with AD, especially during treatment with dupilumab.

AB - BACKGROUND: Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with dupilumab.OBJECTIVE: To survey opinions and experience about conjunctivitis occurring in AD, including those during dupilumab treatment in a group of AD experts from the International Eczema Council (IEC).METHODS: Electronic survey and in-person discussion of management strategies.RESULTS: Forty-six (53.5%) IEC members from 19 countries responded to the survey. Consensus was reached for several statements regarding diagnostic workup, referral and treatment. IEC members suggest that patients with AD should (i) routinely be asked about ocular complaints or symptoms, (ii) obtain information about the potential for conjunctivitis before starting dupilumab therapy and (iii) if indicated, be treated with dupilumab despite previous or current conjunctivitis. In cases of new-onset conjunctivitis, there was consensus that dupilumab treatment should be continued when possible, with appropriate referral to an ophthalmologist.LIMITATIONS: The study relies on expert opinion from dermatologists. Responses from few dermatologists without dupilumab access were not excluded from the survey.CONCLUSION: The IEC recommends that dermatologists address conjunctivitis in patients with AD, especially during treatment with dupilumab.

UR - http://www.scopus.com/inward/record.url?scp=85065301744&partnerID=8YFLogxK

U2 - 10.1111/jdv.15608

DO - 10.1111/jdv.15608

M3 - Journal article

C2 - 31056788

SN - 0926-9959

VL - 33

SP - 1224

EP - 1231

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 7

ER -

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion

Abstract

Access to Document

AUB Link

Other files and links

Fingerprint

Cite this